Biogen (BIIB) Competitors $132.22 -0.43 (-0.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$134.05 +1.83 (+1.38%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. AMGN, GILD, IONS, MRNA, PRTA, SAVA, VRTX, ABBV, BMY, and LLYShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Biogen vs. Its Competitors Amgen Gilead Sciences Ionis Pharmaceuticals Moderna Prothena Cassava Sciences Vertex Pharmaceuticals AbbVie Bristol Myers Squibb Eli Lilly and Company Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk. Do analysts rate BIIB or AMGN? Biogen presently has a consensus target price of $185.74, indicating a potential upside of 40.48%. Amgen has a consensus target price of $304.43, indicating a potential upside of 5.81%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biogen is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Amgen 2 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has more volatility and risk, BIIB or AMGN? Biogen has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Which has stronger earnings & valuation, BIIB or AMGN? Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.00$1.63B$10.4612.64Amgen$33.42B4.63$4.09B$12.2323.52 Is BIIB or AMGN more profitable? Amgen has a net margin of 18.96% compared to Biogen's net margin of 15.31%. Amgen's return on equity of 174.71% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Amgen 18.96%174.71%13.12% Does the media refer more to BIIB or AMGN? In the previous week, Amgen had 27 more articles in the media than Biogen. MarketBeat recorded 56 mentions for Amgen and 29 mentions for Biogen. Biogen's average media sentiment score of 1.16 beat Amgen's score of 1.10 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 23 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 36 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders & institutionals believe in BIIB or AMGN? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAmgen beats Biogen on 12 of the 17 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.39B$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.66%4.48%P/E Ratio12.6420.9283.1926.59Price / Sales2.00352.35515.16159.17Price / Cash5.7243.5325.6628.92Price / Book1.159.7811.766.08Net Income$1.63B-$54.01M$3.27B$265.93M7 Day Performance-3.04%0.10%1.13%0.36%1 Month Performance0.20%8.52%8.30%5.58%1 Year Performance-35.43%7.03%62.26%19.67% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.8649 of 5 stars$132.22-0.3%$185.74+40.5%-35.4%$19.39B$9.68B12.647,605Positive NewsAMGNAmgen4.6416 of 5 stars$288.51-1.8%$304.43+5.5%-13.8%$155.29B$34.92B23.5928,000Positive NewsAnalyst RevisionGILDGilead Sciences4.9696 of 5 stars$114.08-0.6%$115.39+1.2%+43.0%$141.38B$28.86B22.7017,600Positive NewsInsider TradeIONSIonis Pharmaceuticals4.4875 of 5 stars$42.07-1.4%$60.92+44.8%-10.6%$6.70B$705M-22.861,069MRNAModerna4.5111 of 5 stars$25.79-4.9%$42.88+66.3%-68.9%$10.04B$3.24B-3.435,800PRTAProthena3.6934 of 5 stars$8.49-3.2%$30.25+256.3%-63.2%$459.17M$135.16M-1.51130SAVACassava Sciences2.0363 of 5 stars$2.18-1.1%$2.00-8.0%-92.1%$105.07MN/A-0.8530Positive NewsVRTXVertex Pharmaceuticals4.94 of 5 stars$388.90-1.6%$497.10+27.8%-21.1%$99.73B$11.02B27.806,100Positive NewsABBVAbbVie4.7077 of 5 stars$207.86-1.3%$214.95+3.4%+7.1%$367.37B$58.33B99.0355,000BMYBristol Myers Squibb4.7 of 5 stars$47.02-1.9%$56.38+19.9%-5.6%$95.70B$48.30B18.9634,100Positive NewsLLYEli Lilly and Company5 of 5 stars$696.87-2.1%$950.17+36.3%-23.7%$659.68B$45.04B45.5647,000Trending NewsAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Amgen Competitors Gilead Sciences Competitors Ionis Pharmaceuticals Competitors Moderna Competitors Prothena Competitors Cassava Sciences Competitors Vertex Pharmaceuticals Competitors AbbVie Competitors Bristol Myers Squibb Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
